## **APC anti-human HLA-DR**

Catalog # / Size: 2408050 / 100 tests

2408045 / 25 tests

Clone: Tü36

**Isotype:** Mouse IgG2b, κ

Immunogen: Human PBL

Reactivity: Human

Preparation: The antibody was purified by affinity

chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and


unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with HLA-DR (clone Tü36) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).

## **Applications:**

**Applications:** Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for

each application.

**Application** 

Notes:

Additional reported applications (of relevant formats) includes Western blotting4, immunoprecipitation4, and *in vitro* blocking5. The LEAF™ purified antibody (Endotoxin <0.1 EU/microg, Azide-Free, 0.2 µm filtered) is recommended for

functional assays (contact our custom solutions team).

Application References:

1. Pawelec G, et al. 1985. Hum. Immunol. 12:165. (FC)

2. Shaw S, et al. 1985. Hum. Immunol. 12:191. (FC)

3. Ziegler A, et al. 1986. Immunobiology. 171:77. (FC)

4. Cebulla CM, et al. 2002. J. Immunol. 169:167. (WB, FC, IP)

5. Khaw LT, et al. 2013. PLOS One. 8:e69521. (Block)

**Description:** HLA-DR is a heterodimeric cell surface glycoprotein comprised of an  $\alpha$  (heavy)

chain and a  $\beta$  (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene

expression are crucial to graft survival.

Antigen References:

1. Thorsby E. 1974. Transplant. Rev. 18:51.

2. Ovigstad E, et al. 1984. Hum. Immunol. 11:207.

3. Servenius B, et al. 1984. EMBO J. 3:3209.

4. Ottenhoff TH, et al. 1985. Hu